Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance

Area of Science:

• Hematology
• Pharmacovigilance
• Clinical Pharmacology

Background:

• Haematological dyscrasias are serious, potentially fatal conditions.
• Accurate reporting of drug-induced blood disorders is essential for establishing causality, incidence, and risk-benefit analysis.
• Current data on haematological adverse drug reactions (ADRs) have limitations that require improvement.

Purpose of the Study:

• To review limitations in available data on haematological ADRs and suggest improvements.
• To list drugs commonly associated with haematological dyscrasias.
• To present guidelines for managing specific drug-induced haematological conditions.

Main Methods:

• Review of existing literature on haematological dyscrasias and ADRs.
• Identification of drugs commonly implicated in blood disorders.
• Synthesis of management principles and guidelines for specific conditions.
• Discussion of general prevention strategies for serious haematological ADRs.

Main Results:

• Commonly associated drugs and their pathogenesis are discussed.
• Key management features include early hematologist/pharmacist involvement and prompt drug withdrawal.
• Guidelines for aplastic anaemia, agranulocytosis, thrombocytopenia, and haemolytic anaemia are provided.
• Granulocyte colony-stimulating factors (G-CSF; GM-CSF) show potential in agranulocytosis management.

Conclusions:

• Effective management hinges on understanding pathogenesis, early intervention, and accurate identification of offending agents.
• Prevention strategies include prescriber education, restricted prescribing, patient instructions, and haematological monitoring.
• Guidelines should be adapted locally and audited for effectiveness.